Glaukos Change in Accounts Receivable 2014-2025 | GKOS

Glaukos change in accounts receivable for the twelve months ending June 30, 2025 was $-0.075B, a 180.16% increase year-over-year.

  • Glaukos annual change in accounts receivable for 2024 was $-0.022B, a 471.58% increase from 2023.
  • Glaukos annual change in accounts receivable for 2023 was $-0.004B, a 22.47% increase from 2022.
  • Glaukos annual change in accounts receivable for 2022 was $-0.003B, a 284.59% decline from 2021.

Glaukos Change in Accounts Receivable 2014-2025 | GKOS

  • Glaukos annual change in accounts receivable for 2024 was $-0.022B, a 471.58% increase from 2023.
  • Glaukos annual change in accounts receivable for 2023 was $-0.004B, a 22.47% increase from 2022.
  • Glaukos annual change in accounts receivable for 2022 was $-0.003B, a 284.59% decline from 2021.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$184.3B
Intuitive Surgical (ISRG)$168.9B
IDEXX Laboratories (IDXX)$51.3B
Edwards Lifesciences (EW)$47.5B
Alcon (ALC)$40.1B
IQVIA Holdings (IQV)$32.1B
DexCom (DXCM)$30B
Mettler-Toledo (MTD)$26.5B
STERIS (STE)$24.5B
Waters (WAT)$17.5B
SONOVA HOLDING (SONVY)$17B
Hologic (HOLX)$14.8B
Penumbra (PEN)$10.4B
Globus Medical (GMED)$8.3B
Sysmex ADR (SSMXY)$8.1B
Masimo (MASI)$7.7B
Teleflex (TFX)$5.7B
TransMedics (TMDX)$4B
Integer Holdings (ITGR)$3.8B
LivaNova (LIVN)$3.1B
Alphatec Holdings (ATEC)$2.4B
PROCEPT BioRobotics (PRCT)$2.3B
Veracyte (VCYT)$2.3B
Artivion (AORT)$2.1B
Nihon Kohden (NHNKY)$1.9B
Elekta AB (EKTAY)$1.9B
Integra LifeSciences Holdings (IART)$1.2B
OPKO Health (OPK)$1.1B
Paragon 28 (FNA)$1.1B
Pulse Biosciences (PLSE)$1.1B